Beactica Therapeutics appoints Head of Chemistry and two new members to its Board of Directors to strengthen its strategic focus on cancer

14 September 2021

Uppsala, Sweden – 14 september 2021

Beactica Therapeutics AB, the Swedish drug discovery & development company, today announced the appointment of a Head of Chemistry and two new members of the Board. The appointments are made to strengthen the organisation as the company further sharpens its strategic focus on developing novel cancer therapeutics.

Dr Peter Brandt is appointed Head of Chemistry and brings with him more than 20 years of industrial experience in drug discovery & development. Before joining Beactica, Peter has held leading positions at AstraZeneca, the Department of Medicinal Chemistry at Uppsala University, KDev Exploratory of Karolinska Development, Beactica, Biovitrum and Karo Bio. Peter is inventor of twenty published drug patent applications and author on more than fifty scientific publications in peer-reviewed journals. Peter was a Postdoctoral Research Scholar at The Royal Danish School of Pharmacy in Copenhagen and holds a doctorate in organic chemistry from The Royal Institute of Technology in Stockholm.

Joining the Beactica Board of Directors are Dr Christina Herder and Dr Ted Fjällman. Dr Christina Herder has more than 25 years of experience in early-phase drug development and business development in the pharmaceutical industry. Her experience includes executive positions at Medivir, Modus Therapeutics, Swedish Orphan Biovitrum (Sobi) and Biovitrum. Christina is also a member of the Board at PCI Biotech Holding, Idogen and Elicera Therapeutics. Christina Herder holds a doctorate from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm University.

Dr Ted Fjällman is a Partner at Flerie Invest. He was the CEO of Prokarium between 2014–2021 and is also a member of the Board at Amarna Therapeutics and a Director of Tekiu. His previous assignments include positions in clinical research at Sahlgrenska University Hospital and in strategy consulting at Sweden’s Royal Academy of Engineering Sciences. Ted holds a Ph.D. in Biotechnology and Immunology from the University of Guelph, Canada.

“We are delighted to welcome Peter Brandt as Head of Chemistry and Christina Herder and Ted Fjällman to the Board.” said Dr Per Källblad, CEO of Beactica Therapeutics. “Their extensive experiences will be very valuable as we accelerate our trajectory towards an advanced niche position in the area of small molecule cancer therapeutics.”

About Beactica Therapeutics

Beactica Therapeutics AB is a specialist drug discovery and development company, committed to the fight against cancer. Beactica is advancing a proprietary pipeline of first-in-class therapeutics by applying its molecular interaction-based drug discovery engine synergistically across multiple small molecule modalities – including allosteric modulators, protein–protein interaction inhibitors and targeted protein degraders (PROTACs). For more information, please visit

Related files:

Read more news from Beactica Therapeutics here.

Stay Updated

Sign up for the Beactica newsletter to receive our latest news and updates